About Insulet Corporation

Insulet Corporation, founded in 2000, revolutionized diabetes management by developing the Omnipod System, the first commercially available tubeless insulin pump. The company's founders recognized that traditional insulin pumps with tubes and wires created barriers to adoption and developed an innovative solution that provides greater freedom and simplicity for people with diabetes. PODD stock price has reflected strong growth as the company expanded its market share in the insulin delivery market and demonstrated the superiority of its differentiated technology platform.

Led by President and CEO Jim Hollingshead, Insulet's management team combines medical device expertise with deep understanding of the diabetes community's needs. The leadership team has successfully scaled manufacturing, expanded international presence, and continued innovation with the launch of advanced products including smartphone-controlled systems. Management's focus on innovation, market expansion, and operational excellence has been instrumental in driving revenue growth and supporting PODD stock price appreciation as the company captures share in the large insulin delivery market.

Insulet operates by developing, manufacturing, and commercializing its proprietary Omnipod platform, which includes the tubeless Omnipod insulin pump and connected ecosystem of products and services. The company serves people with Type 1 and insulin-requiring Type 2 diabetes across multiple geographies, with products covered by major insurance plans. With the global diabetes epidemic driving demand for innovative management solutions and Insulet's differentiated technology offering compelling advantages over traditional pumps and multiple daily injections, PODD represents an attractive investment in the high-growth diabetes technology market with significant runway for continued penetration and expansion.